These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 15566229)

  • 1. [Really only Vioxx?].
    Heinzl S
    Med Monatsschr Pharm; 2004 Nov; 27(11):361. PubMed ID: 15566229
    [No Abstract]   [Full Text] [Related]  

  • 2. Vioxx doctors wooed by Merck are now its foes.
    Tesoriero HW
    Wall St J (East Ed); 2006 Mar; ():B1, B3. PubMed ID: 16578911
    [No Abstract]   [Full Text] [Related]  

  • 3. The lessons of Vioxx--drug safety and sales.
    Waxman HA
    N Engl J Med; 2005 Jun; 352(25):2576-8. PubMed ID: 15972862
    [No Abstract]   [Full Text] [Related]  

  • 4. How to avoid another 'Vioxx'.
    Frantz S
    Nat Rev Drug Discov; 2005 Jan; 4(1):5-7. PubMed ID: 15690595
    [No Abstract]   [Full Text] [Related]  

  • 5. Discontinuation of Vioxx.
    Nutt DJ
    Lancet; 2005 Jan 1-7; 365(9453):28. PubMed ID: 15639676
    [No Abstract]   [Full Text] [Related]  

  • 6. Was Vioxx really that dangerous?
    Park A
    Time; 2005 Feb; 165(9):52. PubMed ID: 15765852
    [No Abstract]   [Full Text] [Related]  

  • 7. Tailoring arthritis therapy in the wake of the NSAID crisis.
    Olsen NJ
    N Engl J Med; 2005 Jun; 352(25):2578-80. PubMed ID: 15972863
    [No Abstract]   [Full Text] [Related]  

  • 8. [General practice study of therapy of acute pain. Patients prefer cox-2 inhibitors].
    MMW Fortschr Med; 2004 May; 146(21):61. PubMed ID: 15373091
    [No Abstract]   [Full Text] [Related]  

  • 9. New use approved for Vioxx.
    FDA Consum; 2002; 36(4):3. PubMed ID: 12184302
    [No Abstract]   [Full Text] [Related]  

  • 10. Intracranial hypertension induced by rofecoxib.
    Jacob S; Rajabally YA
    Headache; 2005 Jan; 45(1):75-6. PubMed ID: 15663617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The lessons of Vioxx.
    Frazier KC
    N Engl J Med; 2005 Sep; 353(13):1420-1; author reply 1420-1. PubMed ID: 16192497
    [No Abstract]   [Full Text] [Related]  

  • 12. [Withdrawal of rofecoxib: a sign to be careful with coxibs in patients with increased cardiovascular risk].
    Bijlsma JW
    Ned Tijdschr Geneeskd; 2004 Oct; 148(44):2162-4. PubMed ID: 15559407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raising the safety bar--the FDA's coxib meeting.
    Okie S
    N Engl J Med; 2005 Mar; 352(13):1283-5. PubMed ID: 15800221
    [No Abstract]   [Full Text] [Related]  

  • 14. The Vioxx fallout.
    Palmer K
    Minn Med; 2005 Mar; 88(3):26-30. PubMed ID: 15852592
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
    Couzin J
    Science; 2005 Feb; 307(5713):1183-5. PubMed ID: 15731414
    [No Abstract]   [Full Text] [Related]  

  • 16. Health Canada lukewarm on Vioxx panel findings.
    Murray S
    CMAJ; 2005 Aug; 173(4):350. PubMed ID: 16103502
    [No Abstract]   [Full Text] [Related]  

  • 17. The Vioxx debacle.
    Alpert JS
    Am J Med; 2005 Mar; 118(3):203-4. PubMed ID: 15745713
    [No Abstract]   [Full Text] [Related]  

  • 18. Increased risk of cardiovascular events with coxibs and NSAIDs.
    Scott DG; Watts RA
    Lancet; 2005 Apr 30-May 6; 365(9470):1537. PubMed ID: 15866299
    [No Abstract]   [Full Text] [Related]  

  • 19. The safety of the perioperative administration of cyclooxygenase-2 inhibitors for post-surgical pain.
    Reuben SS
    Acta Anaesthesiol Scand; 2005 Mar; 49(3):424; author reply 425. PubMed ID: 15752415
    [No Abstract]   [Full Text] [Related]  

  • 20. Balancing risks and benefits in pain medicine: wither Vioxx.
    Gallagher RM
    Pain Med; 2004 Dec; 5(4):329-30. PubMed ID: 15563316
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.